Published by
Ministry of Health, Labour and Welfare

Translated by
Pharmaceuticals and Medical Devices Agency

Revision of Precautions

Suxamethonium chloride hydrate

July 17, 2019

Therapeutic category

Skeletal muscle relaxants

Non-proprietary name

Suxamethonium chloride hydrate

Safety measure

Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General of Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions): Revised language is underlined.

Current	Revision
Contraindications (N/A)	Contraindications Patients after the acute phase of severe thermal burn, after the acute phase of extensive traumatic crush injury, or patients with quadriplegia
Relative Contraindications Patients with a history of severe thermal burn, extensive traumatic crush injury, uraemia, quadriplegia, or digitalis intoxication, or patients to whom digitalis has been administered recently	Relative Contraindications Patients with a history of severe thermal burn (excluding patients after the acute phase of severe thermal burn), extensive traumatic crush injury (excluding patients after the acute phase of extensive traumatic crush injury), uraemia, or digitalis intoxication, or patients to whom digitalis has been administered recently

N/A: Not Applicable, because the section is not included in the current package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp